BioVenture

Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

Xiguang Bio focuses on the production of diagnostic reagents and provides chemiluminescent raw materials and overall system technology solutions.

Chromai is a company specializing in high-performance intelligent liquid chromatography and medical diagnostic solutions. It focuses on independent innovation and aims to contribute to the revitalization of the national industry. Chromai develops advanced medical molecular diagnostics and testing technologies that streamline the diagnostic process. By leveraging a combination of artificial intelligence, Big Data, and Internet of Things (IoT) technologies alongside leading analysis and detection methods, the company is dedicated to enhancing the fields of health in vitro diagnostics (IVD), environmental protection, and scientific instruments. This commitment enables medical users to achieve simplified and efficient diagnostic and testing analyses.

Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.

Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

Enzymaster (Ningbo) Bio-Engineering Co., Ltd. is a biotechnology company focused on the development and commercialization of innovative enzyme catalysis technologies. Founded in 2013 and based in Ningbo, China, the company specializes in the production of custom enzymes and biocatalytic synthesis for various applications, including active pharmaceutical ingredient intermediates, fine chemicals, and consumer goods. Enzymaster's product portfolio features compounds such as L-tert-leucine, Methyl (R)-3-Hydroxybutyrate, and D-Calcium Pantothenate. The company employs advanced techniques in enzyme-directed evolution, strain engineering, and fermentation process development to promote environmentally friendly and safe manufacturing practices across industries such as pharmaceuticals, food, and environmental conservation. Enzymaster is committed to sustainable practices and aims to contribute positively to society and the environment through its carbon-neutral intelligent manufacturing processes.